Indexed In Scopus
  Scopus ID: 21100926589

Formulation and Evaluation of Chitosan Based Sofosbuvir Solid Lipid Nanoparticles

Lahari Priya Maruboyana, Shanmugam Ramaswamy, Putta Manohar Reddy, Ramya Gade, Yamuna Kotta, Lalitha Priyanka Dwarampudi, Vijayaraj Surendran, Nagaprasad Nagaraj and Krishnaraj Ramaswamy


Sofosbuvir is used to suppress hepatitis C virus (HCV). Sofosbuvir, a Biopharmaceutical Classification System (BCS) class III drug, is highly soluble and impermeable. This study focuses on preparation of sofosbuvir polymeric nanoparticles with improved permeability. Sofosbuvir penetrates better into solid lipid nanoparticles (SLNPs). The chitosan polymer loaded the drug into a single particle microemulsion system and analyzed by zeta measurement, transmission electron microscopy (TEM), and entrapment efficiency (EE). In vitro drug delivery was tested on optimized SLNPs. The non-Fickian transport release profile of formulated SLNPs was 60 – 73 nm. The RP-HPLC approach of sofosbuvir used a Phenomenex Luna C18 column (4.6 x 150 mm, 5) and a mobile phase of acetonitrile (ACN):phosphate buffer (60:40 v/v) at 1.0 ml/min, 260 nm detected. Sofosbuvir’s verified analytical method is linear, precise, accurate, and reliable. All parameters had relative standard deviation (RSD) values less than 5 and stability indicated International Conference on Harmonization (ICH) Q1A R (2) study. Improved oral bioavailability and drug permeability.

Published on: October 20, 2023
doi: 10.17756/nwj.2023-s3-098
Citation: Maruboyana LP, Ramaswamy S, Reddy PM, Gade R, Kotta Y, et al. 2023. Formulation and Evaluation of Chitosan Based Sofosbuvir Solid Lipid Nanoparticles. NanoWorld J 9(S3): S544-S551.

Download Citation (XML)